From the earnings.
Operating expenses for the full-year 2018 were $26.9 million, compared to $33.1 million for the full-year 2017, a decrease of approximately 19%. This decrease was due primarily to a $5.7 million, or 23% decrease, in R&D expense, while SG&A expenses remained unchanged.
26.9M per year cash burn, R&D investment declining. SG&A for a compnay not selling anything.
What do you think happens in 9 months, should an FDA miracle not happen?
Market Data 
Markets 
AI
